Cargando…
Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
We investigated whether belimumab treatment impacts on levels of autoantibodies and cytokines of interest in systemic lupus erythematosus (SLE). Longitudinally collected serum samples from 78 belimumab-treated Swedish SLE patients were analysed. Serum cytokine levels were determined using Luminex xM...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278961/ https://www.ncbi.nlm.nih.gov/pubmed/32422945 http://dx.doi.org/10.3390/ijms21103463 |
_version_ | 1783543452313583616 |
---|---|
author | Parodis, Ioannis Åkerström, Emil Sjöwall, Christopher Sohrabian, Azita Jönsen, Andreas Gomez, Alvaro Frodlund, Martina Zickert, Agneta Bengtsson, Anders A Rönnelid, Johan Gunnarsson, Iva |
author_facet | Parodis, Ioannis Åkerström, Emil Sjöwall, Christopher Sohrabian, Azita Jönsen, Andreas Gomez, Alvaro Frodlund, Martina Zickert, Agneta Bengtsson, Anders A Rönnelid, Johan Gunnarsson, Iva |
author_sort | Parodis, Ioannis |
collection | PubMed |
description | We investigated whether belimumab treatment impacts on levels of autoantibodies and cytokines of interest in systemic lupus erythematosus (SLE). Longitudinally collected serum samples from 78 belimumab-treated Swedish SLE patients were analysed. Serum cytokine levels were determined using Luminex xMAP technology, and nuclear antigen autoantibody specificities using addressable laser bead immunoassay. In patients with detectable levels at baseline, interferon (IFN)-α2 levels were lower at month 6 (median; interquartile range (IQR): 8.9; 1.5–54.9 pg/mL) versus baseline (28.4; 20.9–100.3 pg/mL; p = 0.043). Interleukin (IL)-6 (baseline: 7.1; 2.9–16.1 pg/mL) decreased from month 6 (0.5; 0.5–6.3 pg/mL; p = 0.018) and throughout a 24 month follow-up. IL-10 (baseline: 12.6; 2.8–29.7 pg/mL) showed more rapid decreases from month 3 (1.8; 0.6–9.1 pg/mL; p = 0.003). Levels of anti-dsDNA (p < 0.001), anti-Smith antigen (Sm) (p = 0.002), anti-U1 small nuclear ribonucleoprotein (U1RNP) (p < 0.001), anti-Sm-U1RNP complex (p = 0.028), and anti-ribosomal P (p = 0.012) antibodies decreased from month 3 and remained decreased. Anti-Sm positivity at baseline was associated with higher probability and/or shorter time to achieve sustained SLE responder index-4 response (hazard ratio (HR): 2.52; 95% CI: 1.20–5.29; p = 0.015), independently of other factors. Decline of IL-6 levels through month 3 was greater in responders. In summary, belimumab treatment lowered IFN-α2, IL-6, and IL-10 levels, as well as levels of multiple autoantibodies, however after different time spans. Notably, anti-Sm positivity and early decline in IL-6 levels were associated with favorable treatment outcome. |
format | Online Article Text |
id | pubmed-7278961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72789612020-06-15 Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus Parodis, Ioannis Åkerström, Emil Sjöwall, Christopher Sohrabian, Azita Jönsen, Andreas Gomez, Alvaro Frodlund, Martina Zickert, Agneta Bengtsson, Anders A Rönnelid, Johan Gunnarsson, Iva Int J Mol Sci Article We investigated whether belimumab treatment impacts on levels of autoantibodies and cytokines of interest in systemic lupus erythematosus (SLE). Longitudinally collected serum samples from 78 belimumab-treated Swedish SLE patients were analysed. Serum cytokine levels were determined using Luminex xMAP technology, and nuclear antigen autoantibody specificities using addressable laser bead immunoassay. In patients with detectable levels at baseline, interferon (IFN)-α2 levels were lower at month 6 (median; interquartile range (IQR): 8.9; 1.5–54.9 pg/mL) versus baseline (28.4; 20.9–100.3 pg/mL; p = 0.043). Interleukin (IL)-6 (baseline: 7.1; 2.9–16.1 pg/mL) decreased from month 6 (0.5; 0.5–6.3 pg/mL; p = 0.018) and throughout a 24 month follow-up. IL-10 (baseline: 12.6; 2.8–29.7 pg/mL) showed more rapid decreases from month 3 (1.8; 0.6–9.1 pg/mL; p = 0.003). Levels of anti-dsDNA (p < 0.001), anti-Smith antigen (Sm) (p = 0.002), anti-U1 small nuclear ribonucleoprotein (U1RNP) (p < 0.001), anti-Sm-U1RNP complex (p = 0.028), and anti-ribosomal P (p = 0.012) antibodies decreased from month 3 and remained decreased. Anti-Sm positivity at baseline was associated with higher probability and/or shorter time to achieve sustained SLE responder index-4 response (hazard ratio (HR): 2.52; 95% CI: 1.20–5.29; p = 0.015), independently of other factors. Decline of IL-6 levels through month 3 was greater in responders. In summary, belimumab treatment lowered IFN-α2, IL-6, and IL-10 levels, as well as levels of multiple autoantibodies, however after different time spans. Notably, anti-Sm positivity and early decline in IL-6 levels were associated with favorable treatment outcome. MDPI 2020-05-14 /pmc/articles/PMC7278961/ /pubmed/32422945 http://dx.doi.org/10.3390/ijms21103463 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Parodis, Ioannis Åkerström, Emil Sjöwall, Christopher Sohrabian, Azita Jönsen, Andreas Gomez, Alvaro Frodlund, Martina Zickert, Agneta Bengtsson, Anders A Rönnelid, Johan Gunnarsson, Iva Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus |
title | Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus |
title_full | Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus |
title_fullStr | Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus |
title_full_unstemmed | Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus |
title_short | Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus |
title_sort | autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278961/ https://www.ncbi.nlm.nih.gov/pubmed/32422945 http://dx.doi.org/10.3390/ijms21103463 |
work_keys_str_mv | AT parodisioannis autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT akerstromemil autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT sjowallchristopher autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT sohrabianazita autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT jonsenandreas autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT gomezalvaro autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT frodlundmartina autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT zickertagneta autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT bengtssonandersa autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT ronnelidjohan autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus AT gunnarssoniva autoantibodyandcytokineprofilesduringtreatmentwithbelimumabinpatientswithsystemiclupuserythematosus |